The stock of Shree Ganesh Biotech India, a company operating in the Pharmaceuticals & Biotechnology industry, has recorded a fresh 52-week and all-time low price of Rs.0.65 today. This level reflects a continued downward trajectory, with the stock having declined over the last three consecutive trading sessions, resulting in a cumulative return of -4.29% during this period. The recent day’s performance saw the stock underperform its sector by 1.51%, signalling relative weakness compared to its peers.
Technical indicators further highlight the stock’s subdued momentum. Shree Ganesh Biotech India is currently trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This positioning suggests a persistent bearish trend over short, medium, and long-term horizons.
Our latest weekly pick is out! This Large Cap from Steel/Sponge Iron/Pig Iron delivered with target price and complete analysis. See what makes this week's selection special!
- - Latest weekly selection
- - Target price delivered
- - Large Cap special pick
Comparing the stock’s performance over the past year, Shree Ganesh Biotech India has recorded a return of -37.38%, contrasting sharply with the Sensex’s gain of 9.94% over the same period. The Sensex itself opened higher today at 85,470.92 points, up by 284.45 points or 0.33%, and is currently trading near its 52-week high of 85,290.06. The broader market’s strength, led by mega-cap stocks, underscores the relative underperformance of Shree Ganesh Biotech India.
Financially, the company’s recent results reveal several areas of concern. For the nine months ended September 2025, net sales stood at Rs.5.16 crores, reflecting a contraction of 44.64% compared to the previous period. Correspondingly, the profit after tax (PAT) registered a loss of Rs.0.61 crores, also showing a decline of 44.64%. These figures indicate a significant reduction in revenue generation and profitability.
Additional financial ratios point to challenges in operational efficiency and financial health. The company’s average EBIT to interest ratio is 0.91, suggesting limited capacity to cover interest expenses from earnings before interest and taxes. Return on equity (ROE) averages at 2.62%, indicating modest profitability relative to shareholders’ funds. Furthermore, the debtors turnover ratio for the half-year period is reported at 0.00 times, highlighting potential issues in receivables management.
Over the past year, the company’s profits have declined by approximately 86.6%, which aligns with the stock’s downward price movement. The stock’s valuation appears risky when compared to its historical averages, reflecting the market’s cautious stance on the company’s financial outlook.
Shree Ganesh Biotech India or something better? Our SwitchER feature analyzes this micro-cap Pharmaceuticals & Biotechnology stock and recommends superior alternatives based on fundamentals, momentum, and value!
- - SwitchER analysis complete
- - Superior alternatives found
- - Multi-parameter evaluation
Ownership structure reveals that the majority shareholders are non-institutional, which may influence the stock’s liquidity and trading dynamics. The company’s market capitalisation grade is noted as 4, reflecting its micro-cap status within the Pharmaceuticals & Biotechnology sector.
In summary, Shree Ganesh Biotech India’s stock has reached a critical low point at Rs.0.65, driven by subdued sales, losses, and financial ratios that point to constrained earnings and debt servicing ability. While the broader market and sector indices show resilience, the company’s stock remains under pressure, trading below all major moving averages and reflecting a cautious market assessment.
Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →
